Lymphoma

HealthWell Foundation Opens New Fund to Assist B-Cell Lymphoma Patients

Monday, August 3, 2020 - 3:31pm

The condition may grow and spread slowly with few symptoms (also known as indolent lymphoma) or may be very aggressive with severe symptoms.

Key Points: 
  • The condition may grow and spread slowly with few symptoms (also known as indolent lymphoma) or may be very aggressive with severe symptoms.
  • "Phenomenal advances in treatment for B-cell lymphoma are only useful when patients can afford them," said Don Liss, MD, HealthWell Foundation Board Member.
  • Krista Zodet, HealthWell Foundation President, commented on the fund, "People living with B-cell lymphoma can be faced with a multitude of challenges when it comes to managing their disease.
  • A nationally recognized, independent non-profit organization founded in 2003, the HealthWell Foundation has served as a safety net across over 70 disease areas for more than 500,000 underinsured patients.

Celyad Oncology to Announce First Half 2020 Financial Results and Host Conference Call

Monday, August 3, 2020 - 6:00am

Following the press release, Celyad Oncology management will host a conference call on Friday, August 7 at 2 p.m. CEST / 8 a.m. EDT to discuss first half 2020 results and provide an update on the Companys recent progress and upcoming milestones.

Key Points: 
  • Following the press release, Celyad Oncology management will host a conference call on Friday, August 7 at 2 p.m. CEST / 8 a.m. EDT to discuss first half 2020 results and provide an update on the Companys recent progress and upcoming milestones.
  • The conference call will be webcast live and archived within the "Events section of the Celyad Oncology website.
  • Celyad Oncology is a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer.
  • Forward-looking statements may include statements regarding: the safety and clinical activity of Celyad Oncologys pipelines and financial condition, results of operation and business outlook.

DGAP-News: FDA Approves Monjuvi(R) (tafasitamab-cxix) in Combination with Lenalidomide for the Treatment of Adult Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Saturday, August 1, 2020 - 1:00am

The FDA decision represents the first approval of a second-line treatment for adult patients who progressed during or after first-line therapy.

Key Points: 
  • The FDA decision represents the first approval of a second-line treatment for adult patients who progressed during or after first-line therapy.
  • "The FDA approval of Monjuvi in combination with lenalidomide helps address an urgent unmet medical need for patients with relapsed or refractory DLBCL in the United States," said Herv Hoppenot, Chief Executive Officer, Incyte.
  • "Today's FDA decision offers new hope for patients with this aggressive form of DLBCL who progressed during or after first-line therapy."
  • The FDA previously granted Fast Track and Breakthrough Therapy Designation for the combination of Monjuvi and lenalidomide in relapsed or refractory DLBCL.

FDA Approves Monjuvi® (tafasitamab-cxix) in Combination With Lenalidomide for the Treatment of Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Saturday, August 1, 2020 - 12:51am

The FDA decision represents the first approval of a second-line treatment for adult patients who progressed during or after first-line therapy.

Key Points: 
  • The FDA decision represents the first approval of a second-line treatment for adult patients who progressed during or after first-line therapy.
  • The FDA approval of Monjuvi in combination with lenalidomide helps address an urgent unmet medical need for patients with relapsed or refractory DLBCL in the United States, said Herv Hoppenot, Chief Executive Officer, Incyte.
  • The FDA approval was based on data from the MorphoSys-sponsored Phase 2 L-MIND study, an open label, multicenter, single arm trial of Monjuvi in combination with lenalidomide as a treatment for adult patients with relapsed or refractory DLBCL.
  • The FDA previously granted Fast Track and Breakthrough Therapy Designation for the combination of Monjuvi and lenalidomide in relapsed or refractory DLBCL.

Peripheral T-Cell Lymphoma (PTCL) Market and Epidemiology Forecast, 2030 - ResearchAndMarkets.com

Thursday, July 30, 2020 - 10:35am

The "Peripheral T-Cell Lymphoma (PTCL) - Market Insights, Epidemiology and Market Forecast - 2030" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Peripheral T-Cell Lymphoma (PTCL) - Market Insights, Epidemiology and Market Forecast - 2030" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • The PTCL market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM PTCL market size from 2017 to 2030.
  • The drug candidate is in Phase II stage of development for Peripheral T-cell lymphoma (PTCL) in Japan.
  • Adcetris and Istodax (Romidepsin) for the first line treatment of PTCL is projected to lead the market with the highest market share in 2030.

HTG Launches New HTG EdgeSeq Pan B-Cell Lymphoma Panel

Tuesday, July 28, 2020 - 9:05pm

TUCSON, Ariz., July 28, 2020 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced the launch and immediate availability of the HTG EdgeSeq Pan B-Cell Lymphoma Panel in the United States and Europe.

Key Points: 
  • TUCSON, Ariz., July 28, 2020 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced the launch and immediate availability of the HTG EdgeSeq Pan B-Cell Lymphoma Panel in the United States and Europe.
  • The HTG EdgeSeq Pan B-Cell Lymphoma Panel is commercially available for purchase in kit form or as a service in HTGs VERI/O laboratory and is available in formats specific to both the Illumina and Thermo Fisher Scientific NGS platforms.
  • The HTG EdgeSeq Pan B-Cell Lymphoma Panel is a research-use only (RUO) panel designed to provide molecular characterization of aggressive, indolent and rare lymphomas by allowing researchers to measure the expression of genes associated with the lymphoma transcriptome.
  • The companys proprietary HTG EdgeSeq technology automates complex, highly multiplexed molecular profiling from solid and liquid samples, even when limited in amount.

Allogene Therapeutics to Report Second Quarter 2020 Financial Results on August 5, 2020

Tuesday, July 28, 2020 - 1:30pm

SOUTH SAN FRANCISCO, Calif., July 28, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) therapies for cancer, today announced that it will report second quarter 2020 financial results on Wednesday, August 5, 2020, prior to the open of the market.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., July 28, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) therapies for cancer, today announced that it will report second quarter 2020 financial results on Wednesday, August 5, 2020, prior to the open of the market.
  • The announcement will be followed by a live audio webcast and conference call at 5:30 AM Pacific Time/8:30 AM Eastern Time.
  • The webcast will be made available on the Company's website at www.allogene.com under the Investors tab in the News and Events section.
  • Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T) therapies for cancer.

ProMab Presents Promising Results in Humanized CD19 CAR-T Cells Trial

Monday, July 27, 2020 - 4:00pm

The study has received very promising results of the safety and efficacy of humanized CD19 CAR-T treatment.

Key Points: 
  • The study has received very promising results of the safety and efficacy of humanized CD19 CAR-T treatment.
  • The results have demonstrated that the humanized CD19 CAR-T cell therapy is safe and effective.
  • Our study with humanized CD19 CAR-T cells for the treatment of relapsed and refractory hematological tumors have demonstrated hope for patients and the future of CAR-T technology, added John Wu.
  • ProMab offers licenses to its existing antibodies and CAR-T/NK cell platform IP in multiple fields of immuno-oncology.

FDA Approves First Cell-Based Gene Therapy For Adult Patients with Relapsed or Refractory MCL

Friday, July 24, 2020 - 7:56pm

Tecartus, a chimeric antigen receptor (CAR) T cell therapy, is the first cell-based gene therapy approved by the FDA for the treatment of MCL.

Key Points: 
  • Tecartus, a chimeric antigen receptor (CAR) T cell therapy, is the first cell-based gene therapy approved by the FDA for the treatment of MCL.
  • "We're seeing continued advances in the field of gene therapy and remain committed to supporting innovation in this promising new area of medicine."
  • MCL is a rare form of cancerous B-cell non-Hodgkin's lymphoma that usually occurs in middle-aged or older adults.
  • Each dose of Tecartus is a customized treatment created using a patient's own immune system to help fight the lymphoma.

U.S. FDA Approves Kite’s Tecartus™, the First and Only CAR T Treatment for Relapsed or Refractory Mantle Cell Lymphoma

Friday, July 24, 2020 - 6:25pm

This approval marks the first CAR T cell therapy approved for mantle cell lymphoma patients and represents a new frontier in the treatment of this disease, said Meghan Gutierrez, Chief Executive Officer at the Lymphoma Research Foundation.

Key Points: 
  • This approval marks the first CAR T cell therapy approved for mantle cell lymphoma patients and represents a new frontier in the treatment of this disease, said Meghan Gutierrez, Chief Executive Officer at the Lymphoma Research Foundation.
  • Todays news builds upon this progress and provides hope to mantle cell patients and their loved ones.
  • Manufacturing speed is especially critical for patients with advanced disease, who are very ill and at risk for quick progression.
  • Kite Konnect provides support for eligible patients receiving Yescarta and Tecartus, and it provides information for the healthcare teams supporting their patients.